What to Expect at the 13th Annual Biologics World Taiwan 2026
Attendees
Join over 300 professionals at 13th Annual Biologics World Taiwan! This is your chance to connect with key industry players, expand your network, and engage in high-level discussions that will shape the future of biologics.
Companies
Meet 100 leading companies driving innovation in the biologics sector. Whether you're looking for new partners or exploring the latest breakthroughs, this is the perfect platform to discover what’s next in the industry.
Speakers
Gain exclusive insights from 40 expert speakers who are shaping the future of biologics. Learn from the best in the field as they share cutting-edge knowledge, practical solutions, and emerging trends you can’t afford to miss.
Concept
As Taiwan accelerates its transformation into a leading biomanufacturing hub under its ‘5+2’ Innovative Industries Plan, Biologics World Taiwan 2026 returns at a pivotal moment for the region’s biotech ecosystem. Building on over a decade of excellence, the conference continues to serve as the country’s premier platform uniting 300+ local and global leaders across biologics manufacturing, R&D, and clinical trials. Taiwan’s government has sharpened its focus on biomedicine, aiming to replicate its semiconductor success story in the biotech sector. This vision is backed by action: in 2025 alone, the government has increased its science and technology budget to NT$146.6 billion (approx. USD 4.6 billion)—a nearly 15% rise—to fund AI-driven medical R&D and national talent development across ministries. The launch of the Taiwan Bio-Manufacturing Corporation (TBMC)—modeled after TSMC and with 40% government ownership—marks a bold step in anchoring Taiwan as a regional powerhouse for biologics manufacturing. Meanwhile, the experience during the COVID-19 pandemic has only deepened Taiwan’s resolve to secure domestic CDMO capacity for advanced biologics, highlighting its importance to national health security.
At this year’s summit, expect deep-dive discussions into: • AI-powered innovations in biologics R&D • Scaling biomanufacturing capacity with CDMO excellence • Gene and cell therapy advancements, including CAR-T and stem cell applications • Optimisation in upstream and downstream processes • Case studies on mRNA, HIV, and dengue vaccine development • Taiwan's strategy for global biotech market expansion With 172 biotech companies officially recognised by the MOEA, and several already listed on international stock exchanges, Taiwan’s biologics industry is on the cusp of something extraordinary. Biologics World Taiwan 2026 offers the unmatched opportunity to engage with frontrunners such as PharmaEssentia, Eirgenix, Medigen Biotechnology Corp, Lumosa Therapeutics, Mycenax, and many more. If you're looking to understand where Taiwan’s biologics industry is heading—and how your organisation can be part of its growth—this is the summit you cannot afford to miss.
WHO
This conference is designed for high-level professionals, including C-Suite Executives, Heads, Presidents, Directors, and Vice Presidents involved in Manufacturing, Bioprocessing Downstream Processing, Upstream Processing, and External Manufacturing. Participants come from a diverse range of biologics manufacturing companies across the Asia-Pacific (APAC) region and beyond, representing both established industry leaders and innovative emerging players.
WHAT
The conference aims to provide a comprehensive platform to evaluate and explore the latest strategies, technologies, and solutions in the field of biologics manufacturing. This includes a deep dive into high-speed and resilient biologics production processes, with a special focus on technological advancements, quality control, regulatory compliance, and operational excellence. Attendees will gain insights into how these innovations are being applied throughout Asia’s clinical trials and rapidly evolving markets, ensuring biologics manufacturing can keep pace with growing demand and technological advancements.
WHY
The contract manufacturing company segment presents a vast array of lucrative opportunities for growth and expansion. As the demand for biologics continues to rise, the Asia-Pacific Biologics CDMO market is projected to experience substantial growth, with an annual rate of 8.3%, reaching a total addressable market cap of USD 752.2 Billion by 2030. The potential for innovation, partnerships, and investment in the region is immense, driven by factors such as cost efficiencies, favorable regulatory environments, and technological progress. By attending this event, participants can position themselves at the forefront of these exciting developments and capitalize on emerging opportunities.
Contact
Charmaine Poh, Business Development Lead
e: [email protected] | p: +65 6983 6133
Patrick Lim, Conference Producer
e: [email protected] | p: +60127237716
Share With Your Network
